A method to estimate the mean lifetime survival increase of statin therapy.
AIM
To propose a method for estimating the lifetime advantage of statins.


METHODS
Kaplan-Meier survival curves from published 4S and LIPID studies with 5.8- and 6.1-year follow-up were digitized. Gompertz distributions were fit up to the end of the trials, and then extrapolated out to the end of the patients' predicted lifetimes for each study.


RESULTS
The method results in a 9.9 (95% CI: 8.7-11.9) and 2.8 (95% CI: 2.3-3.3) years' increases for the statin groups for 4S and LIPID studies, respectively.


CONCLUSION
Previous analysis of the same data was limited by the trials' relatively short run time. As such, we propose a method for correctly estimating the true effect of statin therapy in terms of total lifetime extension.
['Chang|Shu-Ching|SC|', 'Wang|Mansen|M|', 'Beckerman|James G|JG|', 'Sanz|Mark|M|', 'Gluckman|Tyler J|TJ|', 'Grunkemeier|Gary L|GL|']
D006801:Humans D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors D053208:Kaplan-Meier Estimate D008017:Life Expectancy D008136:Longevity D017035:Pravastatin D016032:Randomized Controlled Trials as Topic D019821:Simvastatin D013997:Time Factors
Gompertz distribution statin usage survival analysis